Clinical trial
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive…
NCT00006118 · GERCOR - Multidisciplinary Oncology Cooperative Group, Other · Unknown status
Key facts
| NCT number | NCT00006118 |
|---|---|
| Title | Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer |
| Official title | First Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma of the Bladder With a Combination of Cisplatin-Paclitaxel-Gemcitabine |
| Lead sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, gemcitabine hydrochloride, paclitaxel |
| Start date | Jul 1, 1999 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2008 |
| Countries | France, Monaco |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: